buyNotable
Norbert W Bischofberger bought $1.5M of KRON
President & CEO at Kronos Bio, Inc.. 1,731,056 shares at an average of $0.85, traded Nov 15, 2023, filed Nov 17, 2023.
Conviction score
60Value
$1.5M
1,731,056 shares
Holdings after
2,540,665
+214% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.5M at market
- +10Relative to holdingsHoldings up 214%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-055826, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2023 | POpen-market purchase Common Stock | +1,370,688 | $0.80 | $1.1M | 2,180,297 | Nov 17, 2023 |
| Nov 16, 2023 | POpen-market purchase Common Stock | +262,433 | $1.00 | $262k | 2,442,730 | Nov 17, 2023 |
| Nov 17, 2023 | POpen-market purchase Common Stock | +97,935 | $1.08 | $106k | 2,540,665 | Nov 17, 2023 |
Related signals
Other insiders at Kronos Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | KRONsell Kronos Bio, Inc. | Deborah Knobelman President & Interim CEO | $22k 24,838 shares | -15% | |
| 54Moderate | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $734k 615,518 shares | +6% | |
| 60Notable | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $3.1M 3,005,122 shares | +69% | |
| 30Weak | Kronos Bio, Inc. | Allison Frisbee SR VP, CORP OPERATIONS & LEGAL | $13k 12,105 shares | -6% | |
| 30Weak | Kronos Bio, Inc. | Charles Y Lin SR VP, RESEARCH & DEVELOPMENT | $13k 12,036 shares | -5% | |
| 30Weak | Kronos Bio, Inc. | Elizabeth A Olek SR VP, CLINICAL SCIENCE | $7,765 7,368 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $14k 12,009 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $8,718 7,366 shares | -3% | |
| 35Weak | Kronos Bio, Inc. | Barbara Kosacz COO & General Counsel | $13k 10,676 shares | -1% | |
| 23Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $23k 17,367 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.